Anticancer Therapeutics, Missailidis

Автор: Thurston
Название: Chemistry and Pharmacology of Anticancer Drugs, Second Edition
ISBN: 1439853266 ISBN-13(EAN): 9781439853269
Издательство: Taylor&Francis
Рейтинг:
Цена: 132710.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This book is a comprehensive survey of all families of anticancer agents and therapeutic approaches. The book will acts as an indispensable resource for researchers, medicinal chemists and biomedical scientists. The new edition of this book will also have a Companion Website.

Автор: L. Harivardhan Reddy; Patrick Couvreur
Название: Macromolecular Anticancer Therapeutics
ISBN: 1441905065 ISBN-13(EAN): 9781441905062
Издательство: Springer
Рейтинг:
Цена: 243800.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: Cancer treatment using Macromolecular therapeutics has considerably improved the survival benefit for the patients. This book assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy and conveys the importance of this interdisciplinary field.

Автор: L. Harivardhan Reddy; Patrick Couvreur
Название: Macromolecular Anticancer Therapeutics
ISBN: 1461424925 ISBN-13(EAN): 9781461424925
Издательство: Springer
Рейтинг:
Цена: 243800.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs based on therapeutic targets and elaborates on different classes of anticancer therapeutics.

Автор: Carmen Avendano
Название: Medicinal Chemistry of Anticancer Drugs,
ISBN: 0444528245 ISBN-13(EAN): 9780444528247
Издательство: Elsevier Science
Цена: 162110.00 T
Наличие на складе: Невозможна поставка.
Описание: Antitumour chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book addresses the need for an updated treatment from the point of view of medicinal chemistry and drug design. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells.

These therapies are in their infancy, but they hold promise of more effective therapies with fewer side effects. Resistance to antitumour drugs is another important but normally neglected field.The focus of "Medicinal Chemistry of Anticancer Drugs" is on the mechanism of action of antitumour drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumour agents, aiming at the rationalization of the action of this type of drugs, which would allow the design of new active structures. It presents information in a clear and concise way using a large number of figures.

Historical background provides insights on how the process of drug discovery in the anticancer field has evolved. It offers extensive references to primary literature.

Автор: Teicher
Название: Anticancer Drug Development Guide. 2ed.2004
ISBN: 1588292282 ISBN-13(EAN): 9781588292285
Издательство: Springer
Рейтинг:
Цена: 231990.00 T
Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey provides a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, working with the NCI, and the FDA's role in cancer drug development and setting requirements for approval.